Literature DB >> 199262

Cyclic 3':5'-nucleotide phosphodiesterase determined in various human tissues by DEAE-cellulose chromatography.

H Hidaka, T Yamaki, Y Ochiai, T Asano, H Yamabe.   

Abstract

Tissue extracts from human heart, lung, liver, kidney, skeletal muscle and cerebrum displayed at least 3 distinct cyclic 3':5'-nucleotide phosphodieterase (EC 3.1.4.17) activity peaks (FI, FII, FIII) on DEAE-cellulose chromatography and various properties of these forms were compared in each tissue. FI eluted at about 0.08 M sodium acetate, hydrolyzed cyclic GMP more rapidly than it did cyclic AMP, and cyclic GMP hydrolysis by FI in most tissues was enhanced by a protein activator in the presence of CaCl2. As only high concentrations of cyclic AMP inhibited cyclic GMP hydrolytic activity of FI, the enzyme probably has a low affinity for cyclic AMP. FII eluted at about 0.2 M sodium acetate, hydrolyzed both nucleotides at equal rates, and substrate affinities were relatively low. Cyclic GMP hydrolysis by FII was also stimulated by addition of a protein activator in the presence of CaCl2 and cyclic AMP hydrolysis in this fraction was accelerated by a micromolar fraction of cyclic GMP. FII eluted at about 0.35 M hydrolyzed cyclic AMP preferentially and was insensitive to protein activator. These two cyclic nucleotides act as mutual inhibitors of the hydrolysis in this fraction. Ratio of the cyclic GMP to cyclic AMP hydrolysis was in the order FI, FII, FIII. Four activity peaks were eluted from the cerebral extract and enzymes from this tissue exhibited much the same properties as observed in the other tissues examined herein.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 199262     DOI: 10.1016/0005-2744(77)90095-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Subcellular mechanism of the positive inotropic effect of a new quinolinone derivative OPC-8490 on the dog ventricular myocardium.

Authors:  M Endoh; H Satoh; I Norota; K Hirano; T Hosokawa
Journal:  Heart Vessels       Date:  1991       Impact factor: 2.037

2.  Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants.

Authors:  T J Bloom; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

3.  Production of an antiserum against cyclic nucleotide phosphodiesterase and its use for the immunocytochemical demonstration of this enzyme in rat cerebellum.

Authors:  G Poeggel; H Luppa; W Ludwig; P Borneleit
Journal:  Histochemistry       Date:  1988

Review 4.  Histochemistry of nucleotidyl cyclases and cyclic nucleotide phosphodiesterases.

Authors:  G Poeggel; H Luppa
Journal:  Histochem J       Date:  1988-05

5.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

Review 6.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

7.  Calmodulin in brain of schizophrenics.

Authors:  F Vargas; A Guidotti
Journal:  Neurochem Res       Date:  1980-06       Impact factor: 3.996

8.  Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.

Authors:  T Hosokawa; T Mori; H Fujiki; S Kinoshita; K Takemoto; T Imaizumi; T Noda; M Ohura; M Tominaga; Y Yabuuchi
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.